APR 01, 2021 7:00 AM PDT

The Curious Case of COVID Immunity...a Threat to Vaccination Efforts?

WRITTEN BY: Tara Fernandez

After COVID infection, there’s a spectrum of diversity in how long antibodies against the coronavirus hang around—anywhere from days to years. A recent study indicates that the persistence of antibodies against SARS-CoV-2 may be linked to the severity of the infection that the patient experienced, with important implications to vaccination strategies.

The team of scientists from Duke-NUS tracked a cohort of 164 COVID-19 patients in Singapore over a period of around half a year. During this time, they took blood samples to map the dynamics of virus-neutralizing antibodies and other immune factors. This dataset was used to build a machine learning algorithm for predicting how long-lasting a patient’s antibodies to the coronavirus are likely to be.

“The key message from this study is that the longevity of functional neutralizing antibodies against SARS-CoV-2 can vary greatly, and it is important to monitor this at an individual level. This work may have implications for immunity longevity after vaccination, which will be part of our follow-up studies,” said the study’s corresponding author, infectious disease expert Wang Linfa.

Wang and the team were able to classify patients according to their antibody responses. Around 11 percent of patients did not develop any neutralizing antibodies to the coronavirus. Then there was the “rapid waning” group (26.8 percent), whose antibodies dropped off in a matter of days. The “slow waning” and “persistent” groups maintained neutralizing antibodies (at varying levels) for about six months. A small percentage of patients had a “delayed response,” with antibody levels spiking much later during the recovery period.

For the patients without an observable antibody response, the scientists showed that T cell immunity played a larger role in protecting these individuals.

“Our study examines neutralizing antibodies which are important in protection from COVID-19,” explained corresponding author David Lye. “We found that antibodies against SARS-CoV-2 wane in different people at different rates. This emphasizes the importance of public health and social measures in ongoing pandemic outbreak response.” 

“However, the presence of T-cell immunity provides hope of longer-term protection, which will require more studies and time for epidemiological and clinical evidence to confirm,” added Lye.

According to the authors, this study's results could have important implications on vaccination strategies and other government-led initiatives to return to pre-pandemic normalcy. Differences in antibody waning rates could mean that reinfection is a genuine threat for some, even with natural or vaccine-induced immunity. Additionally, if this tapering of antibody levels occurs in those vaccinated, then annual COVID vaccine rollouts could be necessary to maintain herd immunity.

 



Sources: The Lancet Microbe, Duke-NUS Medical School.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 19, 2020
Immunology
Parasitic Worms Help Unravel the Immune Mechanisms Underlying Chronic Disease
NOV 19, 2020
Parasitic Worms Help Unravel the Immune Mechanisms Underlying Chronic Disease
Parasitic worms known as helminths have a complicated relationship with the immune systems of the hosts they invade. Ter ...
JAN 05, 2021
Immunology
Immune Imbalances Dictate COVID Symptom Severity
JAN 05, 2021
Immune Imbalances Dictate COVID Symptom Severity
COVID symptoms. “As it is often the case for pathogenic infections, the host immune system is a key player in vira ...
JAN 17, 2021
Immunology
A Single Dose Nanoparticle Vaccine for COVID-19
JAN 17, 2021
A Single Dose Nanoparticle Vaccine for COVID-19
In the race for finding the right vaccine for the COVID-19 pandemic, a new vaccine candidate emerged. Researchers at Sta ...
JAN 13, 2021
Immunology
Antibodies Gain the Upper Hand Against Sly Tumors
JAN 13, 2021
Antibodies Gain the Upper Hand Against Sly Tumors
Tumors use ingenious approaches to stay just out of reach of immune cells on patrol and avoid detection. Indeed, cancer ...
FEB 03, 2021
Clinical & Molecular DX
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
FEB 03, 2021
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
Rheumatoid arthritis, or RA, is a painful and debilitating autoimmune disorder of the joints, particularly those of the ...
MAR 09, 2021
Immunology
A 'Plug-and-Play' CRISPR Therapy for Flu and COVID
MAR 09, 2021
A 'Plug-and-Play' CRISPR Therapy for Flu and COVID
Researchers have developed a CRISPR treatment that could potentially treat both viruses that cause COVID-19 and influenz ...
Loading Comments...